ArticleAmerican journal of translational research2025
Efficacy and safety of sacral nerve root magnetic stimulation combined with solifenacin in female patients with overactive bladder.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Electromagnetic stimulation for overactive bladder in myelomeningocele children: randomized controlled trial.European journal of physical and rehabilitation medicine · 2026Trial
- Sacral and Bladder Stimulation Synergistically Treat Post-Stroke Urgency Incontinence.International urogynecology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to assess the efficacy and safety of sacral nerve root magnetic stimulation (SNRMS) combined with solifenacin in female patients with overactive bladder (OAB) symptoms.
methodsA total of 183 female patients with OAB symptoms were prospectively randomized into 2 groups. Ninety-two patients in the combination group accepted SNRMS and solifenacin therapy and 91 patients serving as control accepted only solifenacin therapy. The lower urinary tract symptoms, OAB questionnaire (OAB-q) health-related quality of life (HRQoL), symptom bother score, and overactive bladder syndrome score (OABSS) were compared between the two groups at the end of the second, fourth, and eighth weeks.
resultsThe incidence of lower urinary tract symptoms, including urgency, frequent urination, and incontinence episodes, was significantly lower in the fourth and eighth weeks in patients of the combination treatment group than those in the solifenacin group (
conclusionsThe combination therapy of SNRMS and solifenacin demonstrated significant improvements over solifenacin monotherapy in reducing OAB symptoms in female patients, providing a higher QoL without increasing bothersome adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.